A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.

about

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.

Item

http://www.wikidata.org/entity/Q53077187

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A phase 4 study of nilotinib i ...... in chronic phase: ENESTKorea.

@en

A phase 4 study of nilotinib i ...... in chronic phase: ENESTKorea.

@nl

type

Item

label

A phase 4 study of nilotinib i ...... in chronic phase: ENESTKorea.

@en

A phase 4 study of nilotinib i ...... in chronic phase: ENESTKorea.

@nl

prefLabel

A phase 4 study of nilotinib i ...... in chronic phase: ENESTKorea.

@en

A phase 4 study of nilotinib i ...... in chronic phase: ENESTKorea.

@nl

P1476

A phase 4 study of nilotinib i ...... a in chronic phase: ENESTKorea

@en

P2093

Chul Won Jung

http://www.w3.org/2001/XMLSchema#string

Dae-Young Kim

http://www.w3.org/2001/XMLSchema#string

Hawk Kim

http://www.w3.org/2001/XMLSchema#string

Hoon-Gu Kim

http://www.w3.org/2001/XMLSchema#string

Hun Ho Song

http://www.w3.org/2001/XMLSchema#string

Hyeong-Joon Kim

http://www.w3.org/2001/XMLSchema#string

Inho Kim

http://www.w3.org/2001/XMLSchema#string

Jae-Sook Ahn

http://www.w3.org/2001/XMLSchema#string

Jeong-Ok Lee

http://www.w3.org/2001/XMLSchema#string

Jinny Park

http://www.w3.org/2001/XMLSchema#string

P2860

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Chronic myeloid leukemia in Asia.

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

P304

1814-1823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1450

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29577674

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

5943463

http://www.w3.org/2001/XMLSchema#string